Abstract
Simple SummaryCancer cells have developed a number of mechanisms to overcome anticancer therapy; the active efflux of drugs from cells via multidrug resistance proteins (MRPs) is one of them. MRPs belong to the superfamily of ATP binding cassette (ABC) proteins. It was hypothesized that the inhibition of ABC drug transporter activity during cancer therapy could sensitize drug-resistant tumors and/or improve the initial activity of anticancer agents. We demonstrated that the pharmacological inhibition of ABCC4 increases the migratory rate and invasive protrusion formation in colorectal cancer (CRC). Thus, during the use of ABCC4 inhibitors to reduce chemotherapy resistance or drugs that are potential substrates of ABCC4, the indirect effect on cancer metastasis should be taken into consideration and may be important in selecting a therapy scheme for patients.Colorectal cancer (CRC) presents significant molecular heterogeneity. The cellular plasticity of epithelial to mesenchymal transition (EMT) is one of the key factors responsible for the heterogeneous nature of metastatic CRC. EMT is an important regulator of ATP binding cassette (ABC) protein expression; these proteins are the active transporters of a broad range of endogenous compounds and anticancer drugs. In our previous studies, we performed a transcriptomic and functional analysis of CRC in the early stages of metastasis induced by the overexpression of Snail, the transcription factor involved in EMT initiation. Interestingly, we found a correlation between the Snail expression and ABCC4 (MRP4) protein upregulation. The relationship between epithelial transition and ABCC4 expression and function in CRC has not been previously defined. In the current study, we propose that the ABCC4 expression changes during EMT and may be differentially regulated in various subpopulations of CRC. We confirmed that ABCC4 upregulation is correlated with the phenotype conversion process in CRC. The analysis of Gene Expression Omnibus (GEO) sets showed that the ABCC4 expression was elevated in CRC patients. The results of a functional study demonstrated that, in CRC, ABCC4 can regulate cell migration in a cyclic nucleotide-dependent manner.
Highlights
Colorectal cancer (CRC) treatment is challenging due to the heterogeneous nature of cancer, in which prognosis depends on the tumor type and disease stage
We examined the effect of MK571 on endothelial cells upon endothelial to mesenchymal transition (EndoMT)
We found a correlation between this phenotypic conversion and ABCC4 protein upregulation in HT29 cells overexpressing Snail; in the current study, we propose that ABCC4 protein expression and function are related to epithelial reprogramming in CRC [14]
Summary
Colorectal cancer (CRC) treatment is challenging due to the heterogeneous nature of cancer, in which prognosis depends on the tumor type and disease stage. Despite progress in diagnosis and therapy, metastasis and chemoresistance are two critical processes for the overall survival of CRC patients [1]. 50–60% of patients who are diagnosed with CRC will eventually develop metastatic disease. Metastases develop after first-line chemotherapeutic drug and monoclonal antibody treatments for local disease. Many studies have demonstrated that metastatic CRC presents significant molecular heterogeneity [2,3]. This observation explains the Cancers 2020, 12, 3547; doi:10.3390/cancers12123547 www.mdpi.com/journal/cancers
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.